Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Current Deferred Revenue (2023 - 2025)

Profound Medical (PROF) has 3 years of Current Deferred Revenue data on record, last reported at $445000.0 in Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 6.21% year-over-year to $445000.0; the TTM value through Dec 2025 reached $445000.0, up 6.21%, while the annual FY2025 figure was $445000.0, 6.21% up from the prior year.
  • Current Deferred Revenue reached $445000.0 in Q4 2025 per PROF's latest filing, up from $434000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $721000.0 in Q4 2023 and bottomed at $419000.0 in Q4 2024.
  • Average Current Deferred Revenue over 3 years is $558166.7, with a median of $540500.0 recorded in 2025.
  • Peak YoY movement for Current Deferred Revenue: crashed 41.89% in 2024, then rose 6.21% in 2025.
  • A 3-year view of Current Deferred Revenue shows it stood at $721000.0 in 2023, then plummeted by 41.89% to $419000.0 in 2024, then increased by 6.21% to $445000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $445000.0 in Q4 2025, $434000.0 in Q3 2025, and $694000.0 in Q2 2025.